as on September 18, 2025 at 1:29 am IST
Day's Low
Day's High
0.11%
Downside
2.80%
Upside
52 Week's Low
52 Week's High
54.38%
Downside
7.31%
Upside
Check Alnylam Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$60.5B
EPS (TTM)
3.8648
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-505.15
Industry PE ratio
15.754285714285714
P/B Ratio
0PEG Ratio
-0.49
EBITDA
-123.7M
Revenue (TTM)
2.5B
Profit Margin
-12.96%
Return On Equity TTM
576368800.00%
Track how Alnylam Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.
Alnylam Pharmaceuticals, Inc. in the last 5 years
Lowest (0.00x)
September 17, 2025
Today (-505.15x)
September 17, 2025
Industry (15.75x)
September 17, 2025
Highest (0.00x)
September 17, 2025
Today’s Price to Earnings Ratio: -505.15x
Compare market cap, revenue, PE, and other key metrics of Alnylam Pharmaceuticals, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $60.5B | 252.04% | -505.15 | -12.96% | |
NA | $39.0B | NA | NA | -3.89% | |
BUY | $100.3B | 44.17% | 27.85 | 31.86% | |
BUY | $59.6B | 1.78% | 14.1 | 31.37% |
The Alnylam Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Alnylam Pharmaceuticals, Inc. investment value today
Current value as on today
₹1,69,005
Returns
₹69,005
(+69%)
Returns from Alnylam Pharmaceuticals, Inc. Stock
₹64,406 (+64.41%)
Dollar Returns*
₹4,598 (+4.6%)
Based on 34 analysts
70.59%
Buy
29.41%
Hold
0.00%
Sell
Based on 34 analysts, 70.59% of analysts recommend a 'BUY' rating for Alnylam Pharmaceuticals, Inc.. Average target price of $442.44
Get share price movements and forecasts by analysts on Alnylam Pharmaceuticals, Inc..
What analysts predicted
-1.99%DOWNSIDE
Target Price
$442.44
Current Price
$451.23
Analyzed by
34 Analysts
Target
$442.44
Alnylam Pharmaceuticals, Inc. target price $442.44, a slight downside of -1.99% compared to current price of $451.23. According to 34 analysts rating.
Investment in Alnylam Pharmaceuticals, Inc. Shares on INDmoney has grown by 49.12% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:49.12% versus previous 30 day period
Search interest for Alnylam Pharmaceuticals, Inc. Stock has increased by 122% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:122% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
Alnylam Pharmaceuticals, Inc. has experienced consistent revenue growth over the last four quarters. The revenue increased from $500.91 million to $773.68 million. This represents an average increase of 13.0% per quarter.
Best in 3 Years
In the last 3 years, ALNY has outperformed top 5 stocks with highest market-cap in its industry
Price Rise
In the last 3 months, ALNY stock has moved up by 49.4%
Best in 1 Year
In the last 1 year, ALNY has outperformed top 5 stocks with highest market-cap in its industry
Profit Down
Alnylam Pharmaceuticals, Inc. has seen a decline in its net profit over the last two quarters. The net profit decreased from -$57.47 million to -$66.27 million, which means the company is losing more money. This represents an average decrease of 15.3% in net profit each quarter.
Organisation | Alnylam Pharmaceuticals, Inc. |
Headquarters | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
Industry | Health Technology |
CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer |
Ms. Christine Regan Akinc | Chief Corporate Communications Officer |
Dr. Muthiah Manoharan Ph.D. | Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board |
Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director |
Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP |
Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development |
Ms. Melissa McLaughlin M.B.A. | Chief Human Resources Officer |
Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer |
Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
Alnylam Pharmaceuticals, Inc. share price today is $451.23 as on at the close of the market. Alnylam Pharmaceuticals, Inc. share today touched a day high of $463.88 and a low of $450.74.
Alnylam Pharmaceuticals, Inc. share touched a 52 week high of $484.21 on and a 52 week low of $205.87 on . Alnylam Pharmaceuticals, Inc. stock price today i.e. is closed at $451.23,which is 6.81% down from its 52 week high and 119.18% up from its 52 week low.
Alnylam Pharmaceuticals, Inc. market capitalisation is $0.06T as on .
Indian investors can start investing in Alnylam Pharmaceuticals, Inc. (ALNY) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Alnylam Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Alnylam Pharmaceuticals, Inc. share’s latest price of $451.23 as on September 18, 2025 at 1:29 am IST, you will get 0.0222 shares of Alnylam Pharmaceuticals, Inc.. Learn more about
fractional shares .
Alnylam Pharmaceuticals, Inc. stock has given 252.04% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?